In lung adenocarcinomas, expression of SOX2 but not NANOG was detected in approximately 50% of stage I tumors [29], whereas another study reported NANOG expression without SOX2 [30], hence suggesting a SOX2-independent regulatory mechanism of NANOG expression in these tumors. The gene discussed is SOX2; the disease is lung adenocarcinoma.